50% of patients who were applied have delays in the recurrence of the disease, which generates hope for thousands of patients. pancreatic cancer is one of the most aggressive and difficult to diagnose types of cancer, lethal in 88% of cases.
It is the third leading cause of death in the United States, the seventh in the world. The results of the first-phase clinical trial were published in the journal Nature, in an article led by researchers at Memorial Sloan Kettering Cancer Center.